Propanc Biopharma (PPCB) Competitors

6.3% of ALT5 Sigma shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Propanc Biopharma has lower revenue, but higher earnings than ALT5 Sigma.

ALT5 Sigma has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.59, indicating that its stock price is 259% more volatile than the broader market.

Propanc Biopharma has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Propanc Biopharma's return on equity.

In the previous week, Propanc Biopharma had 4 more articles in the media than ALT5 Sigma. MarketBeat recorded 5 mentions for Propanc Biopharma and 1 mentions for ALT5 Sigma. Propanc Biopharma's average media sentiment score of -0.28 beat ALT5 Sigma's score of -0.32 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Equillium has a consensus price target of $7.67, indicating a potential upside of 225.69%. Given Equillium's stronger consensus rating and higher possible upside, analysts clearly believe Equillium is more favorable than Propanc Biopharma.

In the previous week, Propanc Biopharma had 3 more articles in the media than Equillium. MarketBeat recorded 5 mentions for Propanc Biopharma and 2 mentions for Equillium. Equillium's average media sentiment score of 0.00 beat Propanc Biopharma's score of -0.28 indicating that Equillium is being referred to more favorably in the news media.

Propanc Biopharma has a beta of 3.59, indicating that its stock price is 259% more volatile than the broader market. Comparatively, Equillium has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market.

Equillium has higher revenue and earnings than Propanc Biopharma. Equillium is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Equillium's return on equity of -61.43% beat Propanc Biopharma's return on equity.

27.1% of Equillium shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by company insiders. Comparatively, 17.8% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Propanc Biopharma had 4 more articles in the media than Aadi Bioscience. MarketBeat recorded 5 mentions for Propanc Biopharma and 1 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.35 beat Propanc Biopharma's score of -0.28 indicating that Aadi Bioscience is being referred to more favorably in the news media.

Propanc Biopharma has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Propanc Biopharma's return on equity.

52.1% of Aadi Bioscience shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Propanc Biopharma has higher earnings, but lower revenue than Aadi Bioscience. Propanc Biopharma is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Propanc Biopharma has a beta of 3.59, indicating that its stock price is 259% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

In the previous week, Propanc Biopharma had 4 more articles in the media than Coya Therapeutics. MarketBeat recorded 5 mentions for Propanc Biopharma and 1 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.29 beat Propanc Biopharma's score of -0.28 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Coya Therapeutics has a consensus price target of $16.00, suggesting a potential upside of 227.87%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than Propanc Biopharma.

Coya Therapeutics has higher revenue and earnings than Propanc Biopharma. Coya Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Propanc Biopharma has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Propanc Biopharma's return on equity.

Propanc Biopharma has a beta of 3.59, suggesting that its stock price is 259% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

39.8% of Coya Therapeutics shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by insiders. Comparatively, 12.0% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.